Literature DB >> 25356526

Autologous bone marrow stem cell transplantation in patients with liver failure: a meta-analytic review.

Kewei Wang1, Xiaopan Chen, Jinma Ren.   

Abstract

Autologous bone marrow stem cell (ABMSC) transplantation has been utilized in clinical practice to treat patients with liver failure, but the therapeutic effect remains to be defined. A meta-analysis is essential to assess clinical advantages of ABMSC transplantation in patients with liver failure. A systematic search of published works [eg, PubMed, Medline, Embase, Chin J Clinicians (Electronic edition), and Science Citation Index] was conducted to compare clinical outcomes of ABMSC transplantation in patients with liver failure. Meta-analytic results were tested by fixed-effects model or random-effects model, dependent on the characteristics of variables. A total of 534 patients from seven studies were included in final meta-analysis. Subsequent to ABMSC transplantation, there was no significant improvement in general symptom and signs such as loss of appetite, fatigue, and ascites. Activities of serum ALT were not significantly decreased with weighted mean difference (WMD) of -19.36 and 95% confidence interval (CI) -57.53 to 18.80 (P=0.32). Postoperative level of albumin (ALB) was expectedly enhanced by stem cell transplantation (WMD 2.97, 95% CI 0.52 to 5.43, P<0.05, I(2)=84%). Coagulation function was improved as demonstrated by a short prothrombin time (PT) (WMD -1.18, 95% CI -2.32 to -0.03, P<0.05, I(2)=6%), but was not reflected by prothrombin activity (PTA) (P=0.39). Total bilirubin (TBIL) was drastically diminished after ABMSC therapy (WMD -14.85, 95% CI -20.39 to -9.32, P<0.01, I(2)=73%). Model for end-stage liver disease (MELD) scores were dramatically reduced (WMD -2.27, 95% CI -3.53 to -1.02, P<0.01, I(2)=0%). The advantage of ABMSC transplantation could be maintained more than 24 weeks as displayed by time-courses of ALB, TBIL, and MELD score. ABMSC transplantation does provide beneficial effects for patients with liver failure. Therapeutic effects can last for 6 months. However, long-term effects need to be determined.

Entities:  

Mesh:

Year:  2015        PMID: 25356526     DOI: 10.1089/scd.2014.0337

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  5 in total

1.  Wound healing and fibrosis: current stem cell therapies.

Authors:  Ruth Ellen Jones; Deshka S Foster; Michael S Hu; Michael T Longaker
Journal:  Transfusion       Date:  2019-02       Impact factor: 3.157

Review 2.  Cell Therapy for Liver Disease Using Bioimaging Rats.

Authors:  Junko Haga; Shin Enosawa; Eiji Kobayashi
Journal:  Cell Med       Date:  2016-10-21

3.  The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency.

Authors:  Abdel-Rahman N Zekri; Hosny Salama; Eman Medhat; Sherief Musa; Hanan Abdel-Haleem; Ola S Ahmed; Hanan Abdel Hafez Khedr; Mai M Lotfy; Khaled S Zachariah; Abeer A Bahnassy
Journal:  Stem Cell Res Ther       Date:  2015-06-11       Impact factor: 6.832

4.  Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: a systematic review protocol.

Authors:  Nwe Ni Than; Claire L Tomlinson; Debashis Haldar; Andrew L King; David Moore; Philip N Newsome
Journal:  Syst Rev       Date:  2016-06-14

Review 5.  Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option.

Authors:  Yantian Cao; Bangjie Zhang; Rong Lin; Qingzhi Wang; Jie Wang; Fangfang Shen
Journal:  Gastroenterol Res Pract       Date:  2018-03-04       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.